Testimonial and Neuravi Case Study – (Eamon Brady, Founder and Ex-CEO)
I was CEO of Neuravi from its formation in 2009 until its exit to Johnson & Johnson in 2017 and raised over €40m to bring the business through an exciting journey to exit. Prior to Neuravi I had 20 years’ experience hiring top class engineering talent and building teams capable of developing world class medical technology and I already had extensive experience with the benefits of psychometrics. However, many of the potential partners available in 2011 were focused on serving the bigger corporates and conducting evaluations in large batches. These were never going to be good
partners for a start-up like Neuravi where every hire needs to be thought of as a key talent and so I searched for a like minded partner that could provide the depth of service and customization that is required to build leading edge teams.
David and I quickly partnered after we met and he became a fundamental component of our hiring strategy along with rigorous interviews and reference checking. David’s ability to understand the needs of each role, assess the candidates fit to the role and also unmask problems that got through the other parts of the selection process was instrumental in the creation of a dynamic team and a vibrant culture. This reflected itself in the innovation capabilities of the team (>100 patents), the standard of engineering, the commitment to world class technology and even the quality of conversations with customers all of which shaped the brand of the company in the market.
When we sold the business to J&J in 2017, we had become a team of 35 professionals spread across the US and Europe. J&J recognised the capabilities of the team it acquired and set about building a “Neuro Technology Centre” around the Neuravi core in Galway. Today this research team stands at over 100 Research staff and growing.
I continue to work with David in building other exciting companies including WhiteSwell, a heart failure company pioneering a treatment for patients suffering with Acute Decompensated Heart Failure.